Osteocytic Sclerostin Expression as an Indicator of Altered Bone Turnover
暂无分享,去创建一个
E. Cavalier | P. Evenepoel | W. Van Hul | A. Verhulst | M. Haarhaus | G. Dams | Yentl Huybrechts | P. D’Haese
[1] J. Frazão,et al. Evaluation of Renal Osteodystrophy and Serum Bone‐Related Biomarkers in a Peritoneal Dialysis Population , 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] E. Cavalier,et al. Clinical utility of bone turnover markers in patients with chronic kidney disease , 2022, Current opinion in nephrology and hypertension.
[3] A. Voinescu,et al. Calcium, phosphate, PTH, vitamin D, and FGF-23 in CKD-mineral and bone disorder , 2022, Nutritional Management of Renal Disease.
[4] B. Bammens,et al. Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] S. Giannini,et al. Bone Biopsy for Histomorphometry in Chronic Kidney Disease (CKD): State-of-the-Art and New Perspectives , 2021, Journal of clinical medicine.
[6] Toshitaka Nakamura,et al. Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study , 2021, Calcified tissue international.
[7] J. Frazão,et al. Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4 , 2021, Clinical kidney journal.
[8] Aníbal Ferreira,et al. The Role of Bone Biopsy in the Management of CKD-MBD , 2021, Calcified Tissue International.
[9] M. Cozzolino,et al. The Non-invasive Diagnosis of Bone Disorders in CKD , 2021, Calcified Tissue International.
[10] P. Norman,et al. Circulating Levels of Dickkopf-Related Protein 1 Decrease as Measured GFR Declines and Are Associated with PTH Levels , 2020, American Journal of Nephrology.
[11] A. Bobrowska,et al. Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review , 2020, Advances in Therapy.
[12] T. Slowinski,et al. Relationship between GFR, intact PTH, oxidized PTH, non‐oxidized PTH as well as FGF23 in patients with CKD , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] Huiling Cao,et al. Molecular mechanosensors in osteocytes , 2020, Bone Research.
[14] G. Mortier,et al. WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders , 2020, Frontiers in Endocrinology.
[15] J. Souberbielle,et al. PTH determination in hemodialyzed patients—A laboratory perspective , 2019, Seminars in dialysis.
[16] A. Azmi,et al. Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance. , 2019, Journal of the American Society of Nephrology : JASN.
[17] V. Jorgetti,et al. Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism. , 2019, Bone.
[18] H. Malluche,et al. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers , 2019, Clinical nephrology.
[19] Bert Van Rietbergen,et al. Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. , 2019, The lancet. Diabetes & endocrinology.
[20] P. Stenvinkel,et al. Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients , 2018, Calcified Tissue International.
[21] R. Bandiara,et al. Sclerostin Serum Concentration in Patients with Predialysis Ckd Stage 3-5 , 2018, Indonesian Journal of Kidney and Hypertension.
[22] S. Ott. Cortical or Trabecular Bone: What’s the Difference? , 2018, American Journal of Nephrology.
[23] R. Eastell,et al. Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy. , 2018, Journal of the American Society of Nephrology : JASN.
[24] G. Spasovski,et al. Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative—a position paper , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] K. Hruska,et al. The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology. , 2017, Bone.
[26] V. Jorgetti,et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. , 2017, Kidney international.
[27] M. Vervloet,et al. Circulating markers of bone turnover , 2017, Journal of Nephrology.
[28] B. Meijers,et al. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD , 2017, PloS one.
[29] S. Ott. Renal Osteodystrophy—Time for Common Nomenclature , 2017, Current Osteoporosis Reports.
[30] Zhaowen Zong,et al. Different bone remodeling levels of trabecular and cortical bone in response to changes in Wnt/β‐catenin signaling in mice , 2017, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[31] L. Bonewald. The Role of the Osteocyte in Bone and Nonbone Disease. , 2017, Endocrinology and metabolism clinics of North America.
[32] T. Bellido,et al. Role and mechanism of action of sclerostin in bone. , 2017, Bone.
[33] C. Chiang. The use of bone turnover markers in chronic kidney disease‐mineral and bone disorders , 2017, Nephrology.
[34] M. Greenblatt,et al. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. , 2017, Clinical chemistry.
[35] B. Bammens,et al. Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism , 2016, Transplantation.
[36] S. Moe,et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[37] P. D’Haese,et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism , 2014, Kidney international.
[38] R. Marculescu,et al. Renal elimination of sclerostin increases with declining kidney function. , 2014, The Journal of clinical endocrinology and metabolism.
[39] T. Bellido,et al. Effects of PTH on osteocyte function. , 2013, Bone.
[40] J. Kanis,et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[41] P. Dechow,et al. Repression of osteocyte Wnt/β‐catenin signaling is an early event in the progression of renal osteodystrophy , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[42] N. Loveridge,et al. Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[43] P. Torres,et al. Three feedback loops precisely regulating serum phosphate concentration. , 2011, Kidney international.
[44] A. Evdokiou,et al. Sclerostin is a locally acting regulator of late‐osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE‐ASARM‐dependent mechanism , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[45] Mark L. Johnson,et al. Osteocytes, mechanosensing and Wnt signaling. , 2008, Bone.
[46] F. Natt,et al. Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[47] G. Eknoyan,et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.
[48] R. Jilka,et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. , 2005, Endocrinology.
[49] Peng Liu,et al. Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling* , 2005, Journal of Biological Chemistry.
[50] R. Bouillon,et al. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. , 1990, Clinical chemistry.
[51] C. J. Robinson. The physiology of parathyroid hormone. , 1974, Clinics in endocrinology and metabolism.